Theralase Technologies Inc. announce that it's lead compound, RuvidarTM, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with National Microbiology Laboratory and Theralase® Technologies Inc. Heliyon is an all-science, open access journal that is part of the Cell Press family. Any paper reporting scientifically accurate and valuable research, which adheres to accepted ethical and scientific publishing standards, will be considered for publication. In addition, when the human coronavirus was treated with RuvidarTM, the spike protein remained intact
suggesting that inactivation of coronaviruses by RuvidarTM may be used as a vaccine.